Comparison of the Effects of Tenoxicam and Paracetamol on Postoperative Pain

Comparison of the Efficacy of Tenoxicam, Paracetamol (Acetaminophen), and Tenoxicam-Paracetamol Combination on Postoperative Pain in Double-Jaw Surgery Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05508451

Enrollment

Registered

2022-08-19

Start date

2018-04-01

Completion date

2022-04-01

Last updated

2022-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain, Acute

Keywords

Maxillofacial Orthognathic Surgery; Pain management; Postoperative pain; Tenoxicam

Brief summary

Postoperative pain is generally caused by inflammation and oedema related to tissue trauma. Surgical tissue trauma is caused by many factors such as cotery-related burns, surgical incisions, dissections, and instrumental procedures like cutting, stretching, or compression. The pain stimulus is triggered by mediators released by the traumatic tissue and transmitted to the spinal cord and then to the upper centres of the brain. Tenoxicam is an analgesic, anti-inflammatory, and antipyretic drug with a long duration of action, included in the oxicam subgroup of NSAIDs. Tenoxicam has been studied and found effective for many rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis, gout, extra-articular disorders, bursitis, tendonitis, and osteoarthritis. The primary aim of this study was to compare the effects of tenoxicam, paracetamol, and tenoxicam-paracetamol combination analgesic applications on the postoperative VAS score of double-jaw surgery patients. The secondary aim was to investigate the effects of these interventions on the number of both opioid and rescue analgesic drug consumption postoperatively.

Interventions

PROCEDUREDouble jaw surgery

A type of orthognathic surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients between 18-50 aged of both genders who were scheduled for elective bimaxillary surgery * Classified as American Society of Anesthesiologists (ASA) risk class I or II

Exclusion criteria

* having liver or renal dysfunction * coagulopathy disorder, * having psychiatric or medical conditions that might impair communication or compliance with the study procedures * having allergy or contra-indications to the study drugs .pregnancy. * patients who were planned to undergo additional simultaneous surgical procedures such as genioplasty were not included in the study. -

Design outcomes

Primary

Measure	Time frame	Description
The effects of tenoxicam, paracetamol, and tenoxicam-paracetamol combination on the postoperative 30th minute, first hour and 2th hour VAS (Visual Analog Scale) of double-jaw surgery patients.	at the first hour	VAS ( Pain intensity was assessed on a 100-mm Visual Analog Scale (VAS), where 0 = no pain and 100 = worst possible pain
The effects of tenoxicam, paracetamol, and tenoxicam-paracetamol combination	at the second hour	VAS ( Pain intensity was assessed on a 100-mm Visual Analog Scale (VAS), where 0 = no pain and 100 = worst possible pain

Secondary

Measure	Time frame
The secondary efficacy variable was the number of opioid and rescue drug consumptions during the postoperative 24 hours.	during the postoperative 24 hours.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026